Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery

The goal of this clinical trial is to learn whether applying topical tranexamic acid (TXA) directly to the uterine incision during cesarean delivery can reduce surgical bleeding compared to placebo. The study will include pregnant women aged 18-51 undergoing elective cesarean delivery at term (37 weeks or more). The main questions it aims to answer are: * Does topical TXA shorten uterine closure time? * Does topical TXA reduce the need for additional hemostatic sutures? Researchers will compare women receiving topical TXA to those receiving placebo (normal saline) to see if TXA reduces intraoperative bleeding and improves surgical outcomes. Participants will: * Be randomly assigned to receive either topical TXA or placebo during cesarean delivery. * Have standard surgery and postoperative care identical in both groups. * Provide routine clinical data, including hemoglobin levels and recovery outcomes, from their medical records.

NCT Number	NCT07362992
Lead Sponsor	Wolfson Medical Center Collaborators: Rabin Medical Center, Meir Medical Center, Kaplan Medical Center
Conditions	Cesarean Delivery, Postpartum Hemorrhage (PPH), Intraoperative Blood Loss, Hemostasis
Enrollment	112 participants
Start Date	2026-07-01
Primary Completion	2028-12-01 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-02